Malignant melanoma. Treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow support. 1988

T C Shea, and K H Antman, and J P Eder, and A Elias, and W P Peters, and S Schryber, and W D Henner, and D A Schoenfeld, and L E Schnipper, and E Frei
Department of Medicine, Dana-Farber Cancer Institute, Boston.

Nineteen patients with metastatic malignant melanoma were treated with 20 courses of high-dose combination alkylating agent chemotherapy and autologous bone marrow support. All 20 treatment courses were evaluable for toxic reactions and 17 of 20 courses were assessable for response. Twelve of the 20 courses were given at the phase 2 dose per square meter of cyclophosphamide (5.625 g), cisplatin (165 mg), and carmustine (600 mg). Marrow reconstitution occurred with a median time to recovery of 21 and 24 days for more than 500 neutrophils and more than 20,000 platelets, respectively. The overall response rate was 65%, with one patient achieving a complete response with chemotherapy alone. Ten additional patients achieved partial responses following chemotherapy, of which three were subsequently rendered disease free by surgical resection of single areas of residual tumor. Two of these patients are alive and disease free more than 22 months following chemotherapy and one remains relapse free. The median survival for responding patients was 15.2 months and 8.6 months for the entire group.

UI MeSH Term Description Entries
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D008558 Melphalan An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen. Medphalan,Merphalan,Phenylalanine Mustard,Sarcolysine,Sarkolysin,4-(Bis(2-chloroethyl)amino)phenylalanine,Alkeran,L-PAM,Mustard, Phenylalanine
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010386 Pelvic Neoplasms Tumors or cancer of the pelvic region. Cancer of Pelvis,Pelvic Cancer,Cancer of the Pelvis,Neoplasms of Pelvis,Pelvis Cancer,Pelvis Neoplasms,Cancer, Pelvic,Cancer, Pelvis,Cancers, Pelvic,Cancers, Pelvis,Neoplasm, Pelvic,Neoplasm, Pelvis,Neoplasms, Pelvic,Neoplasms, Pelvis,Pelvic Cancers,Pelvic Neoplasm,Pelvis Cancers,Pelvis Neoplasm
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D002330 Carmustine A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed) BCNU,1,3-Bis(2-Chloroethyl)-1-Nitrosourea,BiCNU,FIVB,N,N'-Bis(2-Chloroethyl)-N-Nitrosourea,Nitrumon
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum

Related Publications

T C Shea, and K H Antman, and J P Eder, and A Elias, and W P Peters, and S Schryber, and W D Henner, and D A Schoenfeld, and L E Schnipper, and E Frei
December 1989, Onkologie,
T C Shea, and K H Antman, and J P Eder, and A Elias, and W P Peters, and S Schryber, and W D Henner, and D A Schoenfeld, and L E Schnipper, and E Frei
August 1994, Bone marrow transplantation,
T C Shea, and K H Antman, and J P Eder, and A Elias, and W P Peters, and S Schryber, and W D Henner, and D A Schoenfeld, and L E Schnipper, and E Frei
May 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
T C Shea, and K H Antman, and J P Eder, and A Elias, and W P Peters, and S Schryber, and W D Henner, and D A Schoenfeld, and L E Schnipper, and E Frei
December 1993, Journal of the National Cancer Institute,
T C Shea, and K H Antman, and J P Eder, and A Elias, and W P Peters, and S Schryber, and W D Henner, and D A Schoenfeld, and L E Schnipper, and E Frei
September 1990, Gynecologic oncology,
T C Shea, and K H Antman, and J P Eder, and A Elias, and W P Peters, and S Schryber, and W D Henner, and D A Schoenfeld, and L E Schnipper, and E Frei
August 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
T C Shea, and K H Antman, and J P Eder, and A Elias, and W P Peters, and S Schryber, and W D Henner, and D A Schoenfeld, and L E Schnipper, and E Frei
April 1989, Cancer,
T C Shea, and K H Antman, and J P Eder, and A Elias, and W P Peters, and S Schryber, and W D Henner, and D A Schoenfeld, and L E Schnipper, and E Frei
September 1983, British journal of cancer,
T C Shea, and K H Antman, and J P Eder, and A Elias, and W P Peters, and S Schryber, and W D Henner, and D A Schoenfeld, and L E Schnipper, and E Frei
September 1985, Journal of the American Academy of Dermatology,
T C Shea, and K H Antman, and J P Eder, and A Elias, and W P Peters, and S Schryber, and W D Henner, and D A Schoenfeld, and L E Schnipper, and E Frei
December 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Copied contents to your clipboard!